Testosterone-Guided Schedule of Androgen Deprivation Therapy (ADT) as an Alternative to A Fixed Schedule In Management Of Prostate Cancer
N/A
18 Years
90 Years
18 Years
90 Years
Not Enrolling
Male
Prostate Cancer
Male
Prostate Cancer
Trial Information
Testosterone-Guided Schedule of Androgen Deprivation Therapy (ADT) as an Alternative to A Fixed Schedule In Management Of Prostate Cancer
Inclusion Criteria:
- Pathological evidence of adenocarcinoma of the prostate
- Receiving an LHRH agonist (in the form of a 3-4 monthly depot) for at least one
year.(They may be receiving additional hormonal medications).
- Serum testosterone level below 1.75 nMol/L
Exclusion Criteria:
- Patients on other clinical trials needing continuous androgen deprivation
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Authority:
Canada: Ethics Review Committee
Study ID:
TADS
NCT ID:
NCT01007825
Start Date:
November 2009
Completion Date:
March 2011
Related Keywords:
- Prostate Cancer
- Androgen Deprivation
- ADT
- Testosterone
- LHRH
- Prostate
- To explore the following
- Saving of cost achieved by dosing the LHRH agonist on the basis of measurement of testosterone as compared to routine 3-monthly injection
- Relation between serum testosterone and time after stopping an LHRH agonist
- Clinical factors that influence recovery of testosterone post-LHRH
- Change in physical function after holding LHRH treatment
- Prostatic Neoplasms
Name | Location |
|---|
